Lipocine

Yahoo Finance • 7 months ago

Lipocine stock maintains Buy rating at H.C. Wainwright amid Phase 3 progress

Investing.com - H.C. Wainwright has reiterated its Buy rating and $8.00 price target on Lipocine Inc (NASDAQ:LPCN) following the company’s second-quarter financial results and clinical progress. The stock, currently trading at $3.04, appea... Full story

Mentioned:

• T

Yahoo Finance • 9 months ago

Lipocine stock maintains Buy rating at H.C. Wainwright on PPD treatment potential

Investing.com - H.C. Wainwright has reiterated a Buy rating and $8.00 price target on Lipocine Inc (NASDAQ:LPCN) following the company’s recent R&D event focused on postpartum depression (PPD (NASDAQ:PPD)) treatment. The research firm hig... Full story